BASF India Q2 FY27: Consol PAT falls 42% YoY to ₹61.7 Cr despite 19% revenue growth
PAT -42.41% YoY · revenue +19.46% · margins compressing
₹4,832.19 Cr
+19.46% YoY
₹61.71 Cr
-42.41% YoY
1.27%
-1.4pp YoY
₹14.3
BASF India's consolidated PAT fell 42.4% year-on-year to ₹61.7 Cr in Q2 FY27 (vs ₹107.2 Cr in Q2 FY26) even as revenue grew 19.5% YoY to ₹4,832.2 Cr, and was down 82.9% sequentially from ₹360.3 Cr in Q1 FY27 — though that base included an ₹18.2 Cr one-off gain on the BASF India Coatings divestment plus a much stronger operating quarter. Net margin compressed to roughly 1.3% from 7.4% in Q1 FY27 and 2.6% a year ago; operating margin (segment EBIT/revenue) fell to about 2.2% versus ~10.8% last quarter and ~4.0% in the year-ago quarter. EPS was ₹14.3 (not annualised) against ₹80.4 in Q1 FY27 and ₹23.3 in Q2 FY26.
Q2 FY-2027 vs prior quarters
The squeeze was concentrated in the commodity-linked segments. Materials (Performance Materials + Monomers) grew revenue 29% YoY to ₹1,464.3 Cr but swung to a ₹0.5 Cr segment loss from a ₹36.4 Cr profit a year ago — the single biggest drag on the consolidated print, consistent with cost/spread pressure since volumes clearly held up. Chemicals (Petrochemicals/Intermediates) also flipped to an ₹8.1 Cr loss from a ₹12.3 Cr profit, and the residual "Others" bucket swung to a ₹6.1 Cr loss. Agricultural Solutions posted a ₹28.6 Cr loss versus a ₹50.1 Cr profit a year ago and ₹77.5 Cr last quarter, but the company itself flags this segment as seasonal, so the swing should be read with that caveat rather than as a standalone red flag. Against this, Nutrition & Care and Industrial Solutions were clear bright spots — segment profit up roughly 604% YoY to ₹65.5 Cr and 80% YoY to ₹83.6 Cr respectively, both outpacing their already-strong revenue growth (+35% and +23% YoY).
The stock went into the print at ₹2,950, down 13.6% over the past month of trading.
For context: revenue is at a 6-quarter high.
No explicit forward guidance provided (management stated 'We will not provide any forecast or outlook regarding future business performance'). Management indicated continued investment in Cellasto (Dahej), dispersions (Mangalore), and renewable energy (75-80% of power from renewables by end of agreements with CleanMax)
No broker consensus for this specific quarter turned up in search, so vsStreet is unknown; full-year FY27 consensus pegs revenue growth near 8.8% and EPS growth near 23%, which this quarter's YoY revenue beat but PAT trajectory does not yet support. Management gave no formal guidance last quarter — it explicitly stated it would not forecast future performance — so there is no outlook to grade this print against; the only trackable commitments are structural: continued renewable-power sourcing (BASF added a 14.18% stake in Clean Max Galapagos on Aug 4, 2026, toward its 75-80%-renewable-power target) and the Agri Solutions demerger, which shareholders approved on Jun 24, 2026 and which the company is targeting for an H1 2027 listing, still subject to regulatory approvals. The quarter also saw BASF announce closure of its Dahej Care Chemicals plants by year-end (Aug 4, 2026) even as the Nutrition & Care segment it sits within delivered the quarter's strongest growth, and the company is separately evaluating a new MDI investment at Dahej (Sep 21, 2026) in the same Materials franchise that just posted a loss.
W1
Whether Materials/Chemicals segment margins recover in H2 FY27 from this quarter's swing to losses, including the new Dahej MDI investment BASF is evaluating (announced Sep 21, 2026) in the same Materials franchise
W2
Agri Solutions demerger progress toward the H1 2027 listing target (shareholders approved Jun 24, 2026; NCLT/regulatory approvals pending)
W3
Impact of the Dahej Care Chemicals plant closure (announced Aug 4, 2026, effective year-end) on the Nutrition & Care segment that just delivered the quarter's strongest growth